v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Expense

The following table presents the Company’s segment expense for the three and six months ended June 30, 2025 and 2024:

 

Oncology Segment

 

 

Oncology Segment

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

 

(in thousands)

 

Revenue

 

$

3,181

 

 

$

19,875

 

 

$

8,573

 

 

$

26,346

 

Less R&D expenses:

 

 

 

 

 

 

 

 

 

 

 

 

       TNG462 direct program expenses

 

 

5,577

 

 

 

3,957

 

 

 

11,038

 

 

 

9,043

 

       TNG456 direct program expenses

 

 

1,646

 

 

 

-

 

 

 

2,970

 

 

 

-

 

       TNG260 direct program expenses

 

 

1,809

 

 

 

3,763

 

 

 

3,539

 

 

 

5,999

 

       TNG961 direct program expenses

 

 

1,572

 

 

 

-

 

 

 

3,793

 

 

 

-

 

       TNG908 direct program expenses*

 

 

1,235

 

 

 

3,260

 

 

 

2,947

 

 

 

7,518

 

       TNG348 direct program expenses**

 

 

-

 

 

 

1,641

 

 

 

-

 

 

 

4,941

 

       Discovery direct program expenses

 

 

2,709

 

 

 

7,514

 

 

 

7,388

 

 

 

13,025

 

       Personnel-related expenses

 

 

12,834

 

 

 

13,108

 

 

 

26,684

 

 

 

25,906

 

       Facilities and other related expenses

 

 

5,425

 

 

 

5,411

 

 

 

10,890

 

 

 

10,287

 

Less G&A and other expenses:

 

 

 

 

 

 

 

 

 

 

 

 

       Other segment expenses (a)

 

 

9,227

 

 

 

6,772

 

 

 

18,053

 

 

 

13,092

 

Segment net loss

 

$

(38,853

)

 

$

(25,551

)

 

$

(78,729

)

 

$

(63,465

)

 

*In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.